Harinad Maganti
PhD
Research scientist
Scientific director, Cellular Therapies Research and Development
Other Titles/Affiliations:
Adjunct professor, Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa
Research areas
- hematopoietic stem cell biology and therapies
- genetic engineering
- epi-transcriptomics
- “off the shelf” immune cell therapies
- GMP manufacturing
Brief biography
Dr. Harinad (Hari) Maganti is a Research Scientist at Canadian Blood Services in Ottawa, Ontario. He completed a Master’s of Science in Microbiology at McMaster University and a Doctor of Philosophy in Immunology and Stem Cell Biology at the University of Ottawa. Dr. Maganti also received postdoctoral training in neuroscience at the Hospital for Sick Children as well as postdoctoral training in hematology and stem cell biology at Canadian Blood Services.
Research interests
Dr. Harinad (Hari) Maganti focuses on hematopoietic stem cell transplantation (HSC) which is the only curative therapy for over 30 illnesses. However, HSCs are rare and the molecular mechanisms that govern HSC cell fate decisions are not well characterized. The overarching goal of his laboratory is to discover novel molecular programs/bioengineering technologies that lay the foundation for the development of new HSC products and universal adoptive cellular products for cellular therapy. We use unbiased systems biology and integrative approaches to build gene-regulatory networks (GRNs) using omics (bulk-RNA-seq, ATAC-seq, ChIP-seq, single-cell RNA-seq) data my team has generated in house. The GRNs are subsequently tested using reductionist approaches using CRISPR-Cas9 genome engineering technology to identify “drivers” of HSC fate.
Awards
- American Society of Hematology Scholar Award, 2024